Bionano Genomics (BNGO) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 Good day, and welcome to the Bionana First Quarter twenty twenty five Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to David Holmes from Investor Relations. Please go ahead. Speaker1 Thank you, Lisa, and good afternoon, everyone. Welcome to Bionano First Quarter twenty twenty five Financial Results Conference Call. Leading the call today is Doctor. Eric Hol ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38613 ________________________________________________ ...

Q1 2025 Financial Results 2025 Outlook We anticipate the following results for Q2 2025 and the full year: Webcast Details Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress Conference call today, May 14, 2025, at 4:30 PM ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents the first full quarter of execution after shifting strategy ...

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit.   We are pleased to see consistent utilization of our OGM systems and software combined with a year-over ...

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionano.com Conference Call & Webcast Details CONTACTS | Date: | Wednesday, May 14, 2025 | | --- | --- | | Time: | 4:30 p.m ...

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced the publication in the American Journal of Hematology of expert recommendations from the International Consortium for Optical Genome Mapping (ICOGM) for the integration of OGM as a standard-of-care (SOC) cytogenetic assay for diagnostic workflows in various clini ...

SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis of MM samples, by methods such as FISH or OGM, can be problematic because it is chal ...

Core Insights - Bionano Genomics has announced a study that presents a new method for analyzing multiple myeloma (MM) using optical genome mapping (OGM), which addresses challenges in traditional cytogenetic analysis [1][3] - The study indicates that the new OGM method can reduce the required number of CD138-positive cells for analysis by half, making it easier to analyze limited samples [1][7] - OGM has shown a 93% concordance rate with the traditional FISH method while uncovering over 22 additional genetic variants not detected by FISH, enhancing the understanding of MM [7] Company Overview - Bionano Genomics specializes in genome analysis solutions aimed at transforming genomic research through OGM technology, diagnostic services, and software [4] - The company provides OGM solutions applicable across various research fields, including basic, translational, and clinical research [4] - Bionano also offers a platform-agnostic genome analysis software and nucleic acid extraction solutions using proprietary isotachophoresis technology [4] Industry Context - Multiple myeloma is a significant focus for researchers looking to implement OGM in routine clinical use, highlighting a substantial unmet medical need in the field of hematologic malignancies [3] - The publication of the study is seen as a pivotal advancement for OGM research in the context of blood cancers, potentially expanding the application of OGM in clinical settings [3][8]

Bionano Genomics (BNGO) Q4 2024 Earnings Call April 01, 2025 12:07 AM ET Company Participants David Holmes - Managing DirectorErik Holmlin - President and Chief Executive OfficerVidyun Bais - Equity Research - Vice President Conference Call Participants Sung Ji Nam - Managing Director, Senior Equity Research AnalystMichael Okunewitch - Senior Biotechnology Analyst Operator Good day, and welcome to the Bionana Fourth Quarter twenty twenty four Earnings Conference Call. Today's conference is being recorded. A ...

Bionano Genomics, Inc. (BNGO) Q4 2024 Earnings Conference Call March 31, 2025 04:30 PM ET Company Participants Sanjeev - Conference Call Participant Michael Akunowicz - Conference Call Participant (asking on behalf of Jason McCarthy, Maximum Group) David Holmes - Investor Relations Representative Dr. Eric Holman - CEO and Principal Financial Officer Vivian - Conference Call Participant (asking on behalf of Mark Massaro, BTIG) Operator - Conference Call Operator Sung Jung Yam - Conference Call Participant (S ...